Lumida
/ETON
⌘K
Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc

ETON
$42.32USD↑+13.79%+5.13 today

MARKET CAP

1.2B

P/E (TTM)

—

FWD P/E

37.9x

DAY RANGE

$37 – $43

52W RANGE

$14
$43

AI Summary

Stalk
StalkMedium

ETON remains in a sustained Stage 2 uptrend reinforced by a Momentum Breakout, but extreme overbought readings and a large extension above EMAs suggest timing is unfavorable. Deferred entry near the 9/20/50 EMA support zone is preferred.

  • ↑Q1 ’26 revenue climbed 73% YoY to $24.3M, with FY26 guidance now >$120M
  • ↑Adjusted EBITDA margin reached 24% in Q1 and is projected above 30% for 2026
  • ↓Negative net margin of -1.7% and ROE of -5.7% highlight weak profitability
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Eaton Pharmaceuticals (NASDAQ: ETON) operates within the biopharmaceutical sector, focusing on developing and marketing innovative treatments specifically for rare diseases, with an emphasis on pediatric endocrinology. The company’s strategy hinges on expanding its product portfolio and leveraging recent acquisitions to create strong growth potential in unmet therapeutic markets. Their notable products include Increlix and Alkindi Sprinkle, positioning the company as a player able to address niche patient needs effectively.

Bull says

  • ↑Q1 ’26 revenue climbed 73% YoY to $24.3M, with FY26 guidance now >$120M
  • ↑Adjusted EBITDA margin reached 24% in Q1 and is projected above 30% for 2026
  • ↑Hemangiol acquisition and launch could become Eaton’s largest product by 2027
  • ↑Analysts assign a $41–$57 consensus target, indicating meaningful upside
  • ↑Pipeline expansion in pediatric rare diseases drives long-term growth
  • ↑Positive momentum and favorable rate sensitivity support stock performance

Bear says

  • ↓Negative net margin of -1.7% and ROE of -5.7% highlight weak profitability
  • ↓Heavy reliance on Hemangiol exposes revenue concentration risk by 2027
  • ↓Insider sale of 50,000 shares suggests internal confidence uncertainty
  • ↓$0.9M in new FDA program fees will pressure G&A expenses
  • ↓Negative earnings yield indicates valuation and profit generation concerns
  • ↓Low profitability and size scores point to balance sheet and liquidity risks

Investment themes with ETON

Pharmaceuticals↑ +0.79%

Drug development driving global healthcare solutions

LLY · JNJ · MRK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-20-2026bullish

Transcript signals

Bull points

  • First quarter revenue increased 40% to $24.3 million compared to $17.3 million in the first quarter of 2025
  • Product sales and royalty revenue were $24.3 million during the quarter, compared to $14.0 million in the prior year period, an increase of 73%, driven by strong growth across the portfolio, in particular Increlix, Alkindi Sprinkle, Galzin, and Curcumic Acid, as well as from the addition of sales from Condivi, which was approved and launched in mid-2025
  • Gross profit for the quarter was $14.7 million, compared with $9.9 million in the prior year period, an increase of 49%, primarily due to increased product sales
Read full transcript analysis ›